Early intensive diabetes therapy preserves beta-cell function

July 6, 2012
Early intensive diabetes therapy preserves β-cell function
Early, intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy preserves β-cell function for at least 3.5 years, according to a study published in the July issue of Diabetes Care.

(HealthDay) -- Early, intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy preserves β-cell function for at least 3.5 years, according to a study published in the July issue of Diabetes Care.

Lindsay B. Harrison, M.D., of the University of Texas Southwestern Medical Center in Dallas, and colleagues conducted a randomized trial involving 58 patients with treatment-naive, newly diagnosed . Participants were treated for three months with and and were then randomly allocated to continue with insulin plus metformin or to receive triple oral therapy with metformin, glyburide, and pioglitazone. A mixed meal challenge test was used to assess β-cell function at randomization and six, 12, 18, 30, and 42 months.

After 3.5 years the researchers found that 83 percent of insulin plus metformin-treated patients and 72 percent of triple oral therapy patients completed the study, with good compliance noted in both groups. At 3.5 years after diagnosis, β-cell function was preserved between the groups, with no significant change from baseline or between-group difference (end of study hemoglobin A1c, 6.35 percent for insulin plus metformin versus 6.59 percent for triple oral therapy). In both groups there was an increase in weight, with no significant difference between the groups. Hypoglycemic episodes decreased over time for both groups and were not significantly different.

"Intensive insulin therapy at the time of diagnosis of type 2 followed by either an insulin-based regimen or multiple oral hypoglycemic agents preserves both glycemic control and β-cell function for at least 3.5 years with no significant difference in the adverse-effect profile," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study.

Explore further: Study shows treating diabetes early, intensively is best strategy

More information: Abstract
Full Text

Related Stories

Study shows treating diabetes early, intensively is best strategy

June 28, 2012
Intensive early treatment of type 2 diabetes slows down progression of the disease by preserving the body's insulin-producing capacity, a UT Southwestern study has shown.

Patients with Type 2 diabetes may not benefit from oral medication as well as insulin

April 20, 2012
Patients suffering from type 2 diabetes may not benefit from taking both an oral glucose lowering drug (metformin) and insulin instead of insulin alone, a study published on bmj.com claims.

Researchers test a drug-exercise program designed to prevent type 2 diabetes

December 6, 2011
(Medical Xpress) -- Kinesiology researcher Barry Braun of the University of Massachusetts Amherst and colleagues recently reported unexpected results of a study suggesting that exercise and one of the most commonly prescribed ...

Dapagliflozin aids glycemic control in type 2 diabetes

March 20, 2012
(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research ...

Recommended for you

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

Big strides made in diabetes care

January 5, 2018
(HealthDay)—This past year was a busy, productive one for diabetes research and care.

Gene therapy restores normal blood glucose levels in mice with type 1 diabetes

January 4, 2018
Type 1 diabetes is a chronic disease in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in high blood levels of glucose. A study published January 4th in Cell Stem Cell ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.